Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

22nd Century (XXII) Cash & Equivalents (2016 - 2025)

22nd Century's Cash & Equivalents history spans 15 years, with the latest figure at $4.8 million for Q3 2025.

  • For Q3 2025, Cash & Equivalents fell 9.27% year-over-year to $4.8 million; the TTM value through Sep 2025 reached $4.8 million, down 9.27%, while the annual FY2024 figure was $4.4 million, 114.87% up from the prior year.
  • Cash & Equivalents for Q3 2025 was $4.8 million at 22nd Century, up from $3.1 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $11.0 million in Q1 2023 and bottomed at $1.1 million in Q1 2025.
  • The 5-year median for Cash & Equivalents is $2.4 million (2022), against an average of $3.0 million.
  • The largest annual shift saw Cash & Equivalents soared 591.41% in 2023 before it tumbled 86.15% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $1.3 million in 2021, then surged by 126.05% to $3.0 million in 2022, then crashed by 31.85% to $2.1 million in 2023, then surged by 114.87% to $4.4 million in 2024, then grew by 9.59% to $4.8 million in 2025.
  • Per Business Quant, the three most recent readings for XXII's Cash & Equivalents are $4.8 million (Q3 2025), $3.1 million (Q2 2025), and $1.1 million (Q1 2025).